In January 2020, AM Chemicals LLC entered into a license and supply agreement with Aligos Therapeutics whereby an exclusive license for the right to the use of specific constructs for oligonucleotide therapeutic applications has been granted.
In November 2020, AM Chemicals LLC entered into a license agreement with GeneLink whereby a non-exclusive license for the right to manufacture, market and sell oligonucleotide conjugates using selected GalNAc-modified phosphoramidites and solid supports has been granted.
.png)
In March 2020, AM Chemicals LLC entered into a license and supply agreement with Olix Pharmaceuticals whereby an exclusive license for the right to the use of selected GalNAc-modified phosphoramidites and solid supports for liver targeting strategies has been granted.